[{"id":"c7057663-0031-47ef-b2ee-2af53253f70a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02882659","created_at":"2022-06-06T20:55:01.381Z","updated_at":"2024-07-02T16:37:29.454Z","phase":"Phase 1","brief_title":"Dendritic Killer Cell-based Immunotherapy for Solid Tumors","source_id_and_acronym":"NCT02882659","lead_sponsor":"FullHope Biomedical Co., Ltd.","biomarkers":" CD8 • IFNG • CD69","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FHCT001"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2016-08-30"}]